total
hospit
patient
confirm
pneumonia
immunoglobulin
test
tongji
hospit
retrospect
investig
clinic
laboratori
radiolog
characterist
outcom
data
compar
mildmoder
group
die
group
pair
casecontrol
studi
conduct
deceas
case
match
three
mildmoder
patient
similar
age
among
subject
includ
mildmoder
patient
surviv
case
die
igm
level
peak
forth
week
onset
pneumonia
serum
igg
level
increas
week
serum
igm
level
higher
deceas
patient
mildmoder
patient
p
igg
serum
igm
level
neg
correl
clinic
outcom
eosinophil
count
albumin
level
r
p
r
p
r
p
resp
area
roc
curv
auc
igm
antibodi
ci
p
casecontrol
studi
pair
age
serum
igm
higher
deceas
patient
mildmoder
patient
p
posit
correl
leucocyt
count
r
p
neg
correl
clinic
outcom
albumin
level
r
p
r
p
auc
igm
level
ci
p
result
indic
dynam
specif
igm
igg
antibodi
similar
sarscov
elev
serum
igm
level
indic
poor
outcom
patient
pneumonia
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
coronaviru
diseas
spread
rapidli
worldwid
sinc
discoveri
decemb
march
five
thousand
death
novel
coronaviru
infect
report
countri
effect
strategi
treat
diseas
urgent
need
drug
proven
effect
treatment
pneumonia
antibodi
key
compon
immun
respons
viral
infect
rais
immunoglobulin
igm
immunoglobulin
g
igg
detect
serum
patient
howev
less
inform
avail
dynam
role
pneumonia
therefor
hospit
patient
pneumonia
specif
serum
igm
igg
detect
retrospect
select
februari
march
dynam
role
serum
igm
igg
investig
studi
total
hospit
patient
confirm
pneumonia
serum
igm
igg
examin
februari
march
tongji
hospit
retrospect
investig
brief
patient
mildmoder
group
describ
probabl
hospit
subject
four
ward
tongji
hospit
serum
igm
igg
examin
chest
radiograph
evid
pneumonia
posit
throat
swab
nucleic
acid
test
realtim
rtpcr
method
exclud
studi
studi
review
approv
medic
ethic
committe
tongji
hospit
huazhong
univers
scienc
technolog
irb
inform
collect
accomplish
hospit
electron
medic
record
system
clinic
laboratori
radiolog
paramet
clinic
outcom
obtain
standardis
form
subject
involv
two
research
independ
review
data
serum
igm
igg
antibodi
detect
chemiluminesc
kit
igm
igg
iflash
clia
system
suppli
yhlo
biotech
co
ltd
shenzhen
china
chemiluminesc
kit
complet
eu
ce
certif
threshold
auml
use
igm
igg
manufactur
recommend
statist
softwar
spss
use
studi
categor
variabl
describ
frequenc
rate
percentag
continu
variabl
describ
use
mean
interquartil
rang
iqr
data
normal
continu
variabl
analys
test
otherwis
use
mannwhitney
test
blood
count
patient
admiss
show
significantli
decreas
lymphocyt
especi
die
group
mildmoder
patient
tabl
figur
b
subsequ
explor
correl
igm
level
clinic
outcom
serum
igg
level
blood
count
involv
paramet
interestingli
serum
igm
level
posit
correl
igg
level
r
p
neg
correl
clinic
outcom
eosinophil
count
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
figur
report
antibodi
coronavirus
higher
older
compar
younger
adult
minim
confound
effect
age
pair
casecontrol
studi
done
deceas
case
match
three
mildmoder
patient
similar
age
age
differ
within
four
year
leucocyt
count
neutrophil
count
patient
admiss
significantli
higher
die
group
mildmoder
patient
authorfund
grant
medrxiv
licens
display
preprint
perpetu
figur
also
explor
correl
igm
level
clinic
outcom
serum
igg
level
blood
count
involv
paramet
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
epidemiolog
model
well
studi
effect
drug
develop
host
immun
respons
play
key
role
viru
elimin
histolog
examin
lung
patient
die
reveal
bilater
diffus
alveolar
damag
cellular
exud
accompani
interstiti
mononuclear
inflammatori
infiltr
meanwhil
peripher
cell
count
substanti
reduc
statu
hyperactiv
rais
antibodi
detect
patient
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doiorg
studi
also
limit
singlecentr
retrospect
studi
limit
case
major
patient
admit
hospit
critic
ill
popul
bia
exist
addit
result
viral
load
antibodi
retest
avail
summari
result
demonstr
dynam
igm
igg
antibodi
similar
sarscov
differ
elev
serum
igm
level
indic
poor
outcom
patient
pneumonia
zh
xg
zc
made
substanti
contribut
studi
design
jl
zw
charg
manuscript
draft
zw
hl
took
respons
obtain
ethic
approv
cy
zh
took
respons
data
acquisit
cy
jl
made
main
contribut
data
analysi
interpret
jl
hl
particip
diagnosi
treatment
health
profession
zc
sw
made
substanti
revis
manuscript
author
declar
conflict
interest
permiss
correspond
author
raw
data
without
name
identifi
avail
reason
request
data
provid
public
studi
data
approv
made
public
research
provid
email
address
commun
correspond
author
make
decis
base
research
object
plan
provid
work
support
nation
natur
scienc
foundat
china
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
serum
igm
level
significantli
higher
die
group
casecontrol
studi
accuraci
serum
igm
level
predict
mortal
pair
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
